ADAM10 targeting has also been explored in cancers, such as glioblastoma, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, and breast cancer (reviewed in [74,84]). Here, ADAM10 is linked to non-Hodgkin lymphoma.